Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | Director | June 03, 2026 | June 05, 2026 |
| Taysha Gene Therapies, Inc.TSHA · Entity 4549 | Director | June 01, 2026 | June 02, 2026 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Director | November 22, 2024 | November 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 220,624 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 35,500 · Balance 220,624 F1: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2036-06-03 | Direct | 53,250 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Grant · Acquired 53,250 · Balance 53,250 F2: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
F2: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Taysha Gene Therapies, Inc.
Report date June 01, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,176,559 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 21,335 · Balance 1,176,559 F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.97 · Expires 2036-06-01 | Direct | 42,671 |
Reported balance
After 2026-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-01 · Grant · Acquired 42,671 · Balance 42,671 F3: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 884,290 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 884,290 F2: The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
F2: The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.
F3: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Verrica Pharmaceuticals Inc.
Report date November 22, 2024 · Filed November 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,873,800 |
Ending reported balance
After 2024-11-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-11-22 · Purchase · Acquired 1,123,595 · Balance 1,823,800 F1: The reported securities are included within 1,123,595 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. Row 2 · 2024-11-26 · Gift · Acquired 50,000 · Balance 1,873,800 |
| Series A Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2025-11-22 | Direct | 561,797 |
Reported balance
After 2024-11-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-11-22 · Purchase · Acquired 561,797 · Balance 561,797 F1: The reported securities are included within 1,123,595 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. |
| Series B Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2029-11-22 | Direct | 561,797 |
Reported balance
After 2024-11-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-11-22 · Purchase · Acquired 561,797 · Balance 561,797 F1: The reported securities are included within 1,123,595 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are included within 1,123,595 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dova Pharmaceuticals Inc.
Report date November 12, 2019 · Filed November 12, 2019
Section 16 reporting ended · disclosed 2019-11-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-12 transaction · row 1
1 source rowRow 1 · 2019-11-12 · Other · Disposed 635,665 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 20:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 53,250 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001628280-26-041273 · wk-form4_1780691449.xml · derivative · entry 2 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,250 Underlying: Common Stock · 53,250 shares Expires 2036-06-03 F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-041273 · wk-form4_1780691449.xml · nonDerivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,624 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:30 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 42,671 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001709418-26-000002 · form4-06022026_040616.xml · derivative · entry 3 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,671 Underlying: Common Stock · 42,671 shares Expires 2036-06-01 F3 · derivative.exercise_date: The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:30 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 21,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001709418-26-000002 · form4-06022026_040616.xml · nonDerivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,176,559 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:59 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001576885-25-000082 · wk-form4_1749157011.xml · derivative · entry 2 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2035-06-04 F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:59 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 12,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-25-000082 · wk-form4_1749157011.xml · nonDerivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,124 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 113,246 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001415889-25-015574 · form4-06042025_040609.xml · derivative · entry 3 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,246 Underlying: Common Stock · 113,246 shares Expires 2035-06-02 F3 · derivative.exercise_date: The shares vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:15 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 56,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015574 · form4-06042025_040609.xml · nonDerivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,155,224 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 2, 2026 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| November 26, 2024 Filed Nov 26, 2024 21:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027710 · form4-11262024_041104.xml · nonDerivative · entry 2 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,873,800 Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseSeries B Warrants (right to buy) · Derivative | 561,797 | Not disclosed Strike: $1.34 | Not disclosed |
DisclosureSEC source: 0001415889-24-027710 · form4-11262024_041104.xml · derivative · entry 4 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 561,797 Underlying: Common Stock · 561,797 shares Expires 2029-11-22 F1 · price: The reported securities are included within 1,123,595 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseSeries A Warrants (right to buy) · Derivative | 561,797 | Not disclosed Strike: $1.07 | Not disclosed |
DisclosureSEC source: 0001415889-24-027710 · form4-11262024_041104.xml · derivative · entry 3 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 561,797 Underlying: Common Stock · 561,797 shares Expires 2025-11-22 F1 · price: The reported securities are included within 1,123,595 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 21:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 1,123,595 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027710 · form4-11262024_041104.xml · nonDerivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,823,800 F1 · price: The reported securities are included within 1,123,595 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. Read SEC document |
| June 10, 2024 Filed Jun 10, 2024 20:49 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001576885-24-000082 · wk-form4_1718052537.xml · derivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 10, 2025 or the 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:18 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 98,440 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001415889-24-015041 · form4-05312024_040510.xml · derivative · entry 3 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,440 Underlying: Common Stock · 98,440 shares Expires 2034-05-29 F3 · derivative.exercise_date: The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:18 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantCommon Stock | 49,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015041 · form4-05312024_040510.xml · nonDerivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,098,601 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| August 16, 2023 Filed Aug 17, 2023 00:53 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046152 · doc4.xml · nonDerivative · entry 3 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,049,381 Read SEC document |
| August 16, 2023 Filed Aug 17, 2023 00:53 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | PurchaseCommon Stock | 388,889 | $0.90 | $350,000.10 |
DisclosureSEC source: 0001209191-23-046152 · doc4.xml · nonDerivative · entry 2 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 999,381 Read SEC document |
| August 16, 2023 Filed Aug 17, 2023 00:53 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | PurchaseCommon Stock | 388,889 | $0.90 | $350,000.10 |
DisclosureSEC source: 0001209191-23-046152 · doc4.xml · nonDerivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 884,290 F1 · ownership.nature: The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 20:48 UTC | Taysha Gene Therapies, Inc. TSHA · Entity 4549 | GrantStock Option (right to buy) · Derivative | 43,800 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001209191-23-039730 · doc4.xml · derivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,800 Underlying: Common Stock · 43,800 shares Expires 2033-06-22 F1 · derivative.exercise_date: The shares vest on the earlier of June 22, 2024 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 21:45 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001576885-23-000037 · wk-form4_1686174319.xml · derivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 6, 2024 or the 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 05, 2022 Filed Jul 5, 2022 20:11 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 238,095 | $2.10 | $499,999.50 |
DisclosureSEC source: 0001209191-22-040591 · doc4.xml · nonDerivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,205 Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:24 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001209191-22-037875 · doc4.xml · derivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:17 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionSeries B Preferred · Derivative | 131,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046030 · doc4.xml · derivative · entry 5 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 131,595 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:17 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionSeries A-1 Preferred · Derivative | 130,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046030 · doc4.xml · derivative · entry 4 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 130,180 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:17 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionCommon Stock | 131,595 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046030 · doc4.xml · nonDerivative · entry 3 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 131,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:17 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | PurchaseCommon Stock | 35,000 | $16.00 | $560,000.00 |
DisclosureSEC source: 0001209191-21-046030 · doc4.xml · nonDerivative · entry 2 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,324 Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:17 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionCommon Stock | 130,180 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046030 · doc4.xml · nonDerivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:20 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044956 · doc4.xml · derivative · entry 1 Stalfort John A III · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control. Read SEC document |
| August 14, 2020 Filed Aug 17, 2020 20:39 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 15,700 | $6.38 | $100,166.00 |
DisclosureSEC source: 0001209191-20-046963 · doc4.xml · nonDerivative · entry 2 Stalfort Sean · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,110 F2 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $6.08 to $6.65, inclusive. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 20:39 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 15,550 | $6.45 | $100,297.50 |
DisclosureSEC source: 0001209191-20-046963 · doc4.xml · nonDerivative · entry 1 Stalfort Sean · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,410 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $6.24 to $6.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2). Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 16:40 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | OtherCommon Stock | 635,665 | $27.50 | $17,480,787.50 |
DisclosureSEC source: 0001209191-19-056045 · doc4.xml · nonDerivative · entry 1 Stalfort Sean · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 01:54 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 1,200 | $10.94 | $13,128.00 |
DisclosureSEC source: 0001209191-19-002675 · doc4.xml · nonDerivative · entry 2 Stalfort Sean · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,860 F2 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $10.91 to $11.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 01:54 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | PurchaseCommon Stock | 8,021 | $10.38 | $83,257.98 |
DisclosureSEC source: 0001209191-19-002675 · doc4.xml · nonDerivative · entry 1 Stalfort Sean · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,660 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $9.90 to $10.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:07 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | PurchaseCommon Stock | 31,000 | $6.26 | $194,060.00 |
DisclosureSEC source: 0001209191-18-063954 · doc4.xml · nonDerivative · entry 1 Stalfort Sean · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 635,665 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.02 to $6.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 19, 2018 Filed Jun 19, 2018 20:50 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | ConversionSeries A Convertible Preferred Stock · Derivative | 394,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038600 · doc4.xml · derivative · entry 2 Stalfort Sean · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 394,295 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| June 19, 2018 Filed Jun 19, 2018 20:50 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | ConversionCommon Stock | 394,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-038600 · doc4.xml · nonDerivative · entry 1 Stalfort Sean · CIK 0001709418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.